Sorrento Therapeutics, Inc. (NASDAQ: SRNE) Starts Presentation at LD Micro Main Event
Sorrento Therapeutics (NASDAQ: SRNE) is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies, clinical stage immuno-cellular therapies, intracellular targeting antibodies, antibody-drug conjugates, and clinical stage oncolytic virus. Sorrento's is also advancing a first-in-class (TRPV1 agonist) non-opioid pain management small molecule in Resiniferatoxin and ZTlido. Resiniferatoxin is completing a phase IB trial in terminal cancer patients. ZTlido is in regulatory review. For more information, visit the company’s…
